Patents by Inventor Jeffrey D Kahl

Jeffrey D Kahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazolinone modulators of nuclear receptors
    Patent number: 8748440
    Abstract: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: June 10, 2014
    Assignee: Exelixis, Inc.
    Inventors: Richard Martin, Jeffrey D Kahl, Brenton T Flatt, Ronald Griffith
  • Quinazolinone Modulators Of Nuclear Receptors
    Publication number: 20120064025
    Abstract: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.
    Type: Application
    Filed: September 28, 2011
    Publication date: March 15, 2012
    Applicant: EXELIXIS, INC.
    Inventors: Richard Martin, Jeffrey D. Kahl, Brenton T. Flatt, Ronald Griffith
  • Quinazolinone Modulators Of Nuclear Receptors
    Publication number: 20080070864
    Abstract: Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.
    Type: Application
    Filed: March 4, 2003
    Publication date: March 20, 2008
    Applicant: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Jeffrey D. Kahl, Brenton T. Flatt, Ronald Griffith
  • Heterocyclic modulators of nuclear receptors
    Patent number: 7115640
    Abstract: Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: October 3, 2006
    Assignee: X-Ceptor Therapeutics, Inc.
    Inventors: Richard Martin, Brenton T Flatt, Jeffrey D Kahl, Tie-Lin Wang
  • 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof
    Publication number: 20030171588
    Abstract: The invention relates to combinatorial libraries containing two or more novel piperidine-3-carboxamide derivative compounds, methods of preparing the piperidine-3-carboxamide derivative compounds and piperidine-3-carboxamide derivative compounds bound to a resin
    Type: Application
    Filed: March 7, 2002
    Publication date: September 11, 2003
    Inventors: Jeffrey D. Kahl, Normand Hebert